A combination of anti-platelet and anticoagulant therapy is appropriate for atrial fibrillation patients who are undergoing PCI to mitigate stroke risk, according to a prospective, multicenter study reported in Catheterization and Cardiovascular Interventions. The study also found that vitamin K antagonist therapy should not be discontinued prior to PCI.

Related Summaries